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Abstract 
Background: Higher lifetime antipsychotic exposure has been associated with poorer cognition in schizophrenia. The 
cognitive effects of adjunctive psychiatric medications and lifetime trends of antipsychotic use remain largely unclear. We 
aimed to study how lifetime and current benzodiazepine and antidepressant medications, lifetime trends of antipsychotic 
use and antipsychotic polypharmacy are associated with cognitive performance in midlife schizophrenia. 
 
Methods: Sixty participants with DSM-IV schizophrenia from the Northern Finland Birth Cohort 1966 were examined at 
43 years of age with an extensive cognitive test battery. Cumulative lifetime and current use of psychiatric medications 
were collected from medical records and interviews. The associations between medication and principal component 
analysis-based cognitive composite score were analysed using linear regression. 
 
Results: Lifetime cumulative DDD years of benzodiazepine and antidepressant medications were not significantly 
associated with global cognition. Being without antipsychotic medication (for minimum 11 months) before the cognitive 
examination was associated with better cognitive performance (p=0.007) and higher lifetime cumulative DDD years of 
antipsychotics with poorer cognition (p=0.020), when adjusted for gender, onset age and lifetime hospital treatment days. 
Other lifetime trends of antipsychotic use, such as a long antipsychotic-free period earlier in the treatment history, and 
antipsychotic polypharmacy, were not significantly associated with cognition. 
 
Conclusions: Based on these naturalistic data, low exposure to adjunctive benzodiazepine and antidepressant medications 
does not seem to affect cognition nor explain the possible negative effects of high dose long-term antipsychotic 
medication on cognition in schizophrenia.  
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effect 
 
 
 
 
1. Introduction 
 Antipsychotic medication forms the foundation of the evidence-based pharmacological treatment of schizophrenia [1, 2]. 
Antipsychotic polypharmacy, defined as the concomitant use of 2 or more antipsychotics, and other psychiatric 
medications, such as benzodiazepines and antidepressants, are also widely used in schizophrenia, especially in case of 
incomplete treatment response or comorbid psychiatric symptoms, although their indications and efficacy are less clear [3, 
4, 5]. Neurocognitive deficits are a central dimension of schizophrenia, emerging during deviant neurodevelopment [6], 
being established by the first psychotic episode and staying relatively stable during the illness course for up to 10 years [7, 
8, 9] and also in older persons with schizophrenia [10]. Because of the key role of these deficits in influencing the long-
term outcome in schizophrenia [11], it is important to study the safety and effects of medication on cognition. 
Antipsychotics have been associated with mild to moderate, positive cognitive effects in short-term randomised, 
controlled trials (RCTs) [12, 13, 14], possibly mostly explained by practice effects [15]. Very little is known of the long-
term cognitive effects of antipsychotics in schizophrenia after 2-3 [16] or 5 years of use [17]. In naturalistic studies, higher 
antipsychotic doses [18, 19, 20] or antipsychotic polypharmacy [19] have been associated with poorer cognition, and 
dose-reduction with improved cognition [21, 22]. 
Benzodiazepines are used by patients with schizophrenia for sedation, to treat anxiety and agitation or to combat 
adverse effects of antipsychotics [23]. There is no evidence of efficacy against psychotic symptoms [24] and there are 
concerns about the long-term safety of benzodiazepines, which have been associated with higher mortality in 
schizophrenia [23, 25]. Long-term use of benzodiazepines (mean 10 years) has been associated with cognitive impairment 
in a meta-analysis [26]. In schizophrenia cognitive improvement has been reported after the reduction of long-term (mean 
4-11 years) benzodiazepine use [27, 28].  
Antidepressants have some efficacy in reducing depressive [29] and negative [30] symptoms in schizophrenia, and 
moderate to high antidepressant exposure has been linked to lower mortality [25]. The cognitive effects of antidepressants 
in schizophrenia, studied in clinical trials ranging from 4 to 24 weeks in duration, have been positive, but clinically non-
significant in one recent meta-analysis [31] and review [32]. 
The long-term effects of psychiatric medications in schizophrenia are mostly unknown. Studies on the lifetime use of 
psychiatric medications are rare and limited to antipsychotic medication largely ignoring other psychiatric medications. 
Double-blind RCTs of long-term treatment are the golden standard for the study of treatment effects, but difficult to carry 
out for several years. Naturalistic, observational samples offer a feasible setting to investigate the long-term effects of 
medication [33] and form at least hypotheses for further study. 
Pharmacoepidemiology has been a major study arm of the Northern Finland Birth Cohort 1966 (NFBC 1966) [34]. We 
previously showed that higher lifetime cumulative doses of antipsychotic medication were associated with a decline in 
verbal learning and memory between ages 34 and 43 years [17] and poorer global cognitive performance at the age of 43 
years in schizophrenia [16]. However, prior research, including our own, has mainly focused on associations between 
cognition and antipsychotic medication, and we have not fully considered the possible effects of other psychotropic 
medication. In this study therefore, we aimed to investigate, for the first time, how lifetime cumulative and cross-sectional 
doses of benzodiazepine and antidepressant medications are associated with cross-sectional, global cognition in 
schizophrenia at 43 years of age. We also wanted to prose the effects of lifetime use of antipsychotics, and especially 
antipsychotic polypharmacy, on cognition in more detail than in our previous studies. We hypothesised that higher 
benzodiazepine and antipsychotic use, and antipsychotic polypharmacy, would be associated with poorer cognition and 
antidepressant use with neutral or positive cognitive effects, when potential confounders were taken into account. 
 
2. Methods 
 
2.1 Sample  
 
2.1.1 Participants 
The participants were derived from the unselected, general population based Northern Finland Birth Cohort 1966 
(NFBC 1966) that consists of 12 058 live-born children [35]. The NFBC 1966 members with a lifetime psychosis 
diagnosis were detected from national register data by the end of 2008 and questionnaire data collected in 1997 [36]. 
Persons with a psychosis diagnosis in the Care Register for Health Care, in the Social Insurance Institution of Finland 
registers on sick leaves, disability pensions or the right to reimbursement for psychoactive medication due to psychosis 
and those who reported a psychosis or current antipsychotic use were included. 
This procedure, described in more detail in our earlier work [16], resulted in 257 NFBC 1966 members with a lifetime 
psychosis diagnosis and known address, who were invited. Ninety-nine persons (38.5%) participated in a psychiatric 
examination in 2008-2011 including the SCID I interview leading to DSM-IV lifetime diagnosis. There were 60 (87.0%) 
persons with a diagnosis of schizophrenia spectrum disorder, a completed cognitive test battery and information on 
lifetime antipsychotic medication. Of them 50 (83%) had a DSM-IV lifetime diagnosis of schizophrenia, 6 (10%) 
schizoaffective, 2 (3%) schizophreniform and 2 (3%) delusional disorder. In this article, hereafter, the term schizophrenia 
encompasses schizophrenia and other schizophrenia spectrum disorders. Lifetime antipsychotic dose and cognition at 43 
years of age has been studied in this same sample before [16] and a subsample of it (40 cases, 67%) was analysed in 
another study on lifetime antipsychotic medication and change of verbal learning and memory between 34 and 43 years 
[17]. 
There was selective attrition of participants in educational level, onset age, disability pension status and schizophrenia 
diagnosis, but weighted sensitivity analyses performed in an earlier study of this sample [16] confirmed that attrition did 
not significantly affect the results on cumulative lifetime antipsychotic medication dose and global cognition at age 43 
years. 
 
2.1.2 Ethical considerations 
The Ministry of Social and Health Affairs gave permission to collect data for the NFBC 1966 study. The Ethical 
Committee of the Northern Ostrobothnia Hospital District regularly reviews the study. All participants gave informed 
consent. The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving 
humans was followed.  
 
2.2 Data on psychiatric medication 
Information on the lifetime use of psychiatric medications until the 43-year examination date was collected during 
2007-2016 from all available Finnish hospital and outpatient records. Data collection of antipsychotic medication, 
described in detail elsewhere [17, 37], was completed in 2014 and collection of other psychiatric medications in 2016. 
These data were supplemented with information on current (last 3 months) and earlier use of psychiatric medications 
obtained in an interview in the 43-year study [38] and register of the Social Insurance Institution of Finland on 
psychoactive medications purchased in 1997. Based on this information the cumulative lifetime and current doses of 
psychiatric medications were calculated. 
 
2.3 Neurocognitive assessment 
The neuropsychological examination was performed at the 43-year study using an  extensive neuropsychological 
battery of tests comprising the Abstraction Inhibition and Working Memory task (AIM) [39], California Verbal Learning 
Test (total scores of trials 1-5; CVLT) [40], Visual Object Learning Test (VOLT) [41], Verbal fluency [42], Visual series 
(WMS-III) [43], and Vocabulary, Digit Span and Matrix reasoning (WAIS-III) [44].  
 
2.4 Variables 
 
2.4.1 Neurocognitive variables and the cognitive composite score 
A principal component analysis (PCA) of the eight chosen neurocognitive test variables resulted in a cognitive 
composite score representing global cognitive performance (see 2.5 Statistical analyses) [16]. 
 
2.4.2 Medication variables 
The psychiatric medications were classified according to the Anatomical Therapeutic Chemical (ATC) classification 
system [45] into benzodiazepines (including benzodiazepine derivatives N05BA, N03AE and N05CD; and 
benzodiazepine related drugs N05CF), antidepressants (N06A), antipsychotics (N05A), anticholinergic agents (N04A) 
and other psychiatric medication. 
The medication variables representing lifetime and current use are described in detail in Table 1. The current doses 
were transformed to Defined Daily Dose ratios (DDD ratios) and cumulative exposure to Defined Daily Dose years (DDD 
years) [45].  
 
2.4.4 Background variables 
The analyses were adjusted for relevant background variables and confounders, including gender, age of illness onset, 
markers of severity of illness (logarithmic transformation of cumulative lifetime psychiatric hospital treatment days until 
the study, and remission and PANSS positive, negative and disorganisation symptoms, classified based on the factor 
structure described by van der Gaag et al. [46], at the time of the study), educational level (Supplementary material, 
Methods) and current antipsychotic dose and benzodiazepine and antidepressant use (Table 1). 
 
2.5 Statistical analyses 
The measure of global cognitive performance was derived from a principal component analysis (PCA) of the cognitive 
test variables (Immediate free recall of trials 1–5 of CVLT, total scores of VOLT, AIM, Verbal fluency, Visual series, 
Vocabulary, Digit Span and Matrix reasoning). Missing values of the cognitive tests (one case was missing an AIM score, 
2 a VOLT score and 3 both VOLT and AIM scores) were predicted using multiple imputation (20 datasets) [47] with fully 
conditional specification (MCMC) method and linear regression as model type using data from all eight cognitive test 
variables. The PCA (eigenvalue set as >1) resulted in one cognitive factor (cognitive composite score), which explained 
52.9% of total variance. Communalities were between 0.32 and 0.66 and factor loadings between 0.57 and 0.81.  
The associations between the cognitive composite score and psychiatric medication variables were analysed using 
linear regression analysis. The natural logarithm of DDD years of lifetime psychiatric medications to correct for their 
skewness and non-transformed other psychiatric medication variables were used as predictor variables. The effects of 
medication variables in the linear regression models are presented as unstandardised regression coefficients (B) and their 
standard error (SE), standardised regression coefficients (Beta) and p-values. As post hoc analyses, the means of the 
composite score with 95% confidence intervals were plotted in the high-, medium- and low-dose groups of the cumulative 
DDD years of medication (divided based on tertiles). P-values < 0.05 were considered statistically significant. The 
analyses were performed using IBM SPSS Statistics 24 [48]. 
 
3. Results  
 
3.1 The characteristics of the sample  
The characteristics of the sample are described in Table 2. The sample consisted of 60 cases (33 males, 55%) with 
lifetime schizophrenia. The mean duration of illness of the sample was 16.5 years (SD 6.0) and average age was 43.1 
years (SD 0.8). 
 
3.2 The characteristics of medication use 
The lifetime and current use and doses of antipsychotic, benzodiazepine and antidepressant medications are presented 
in Table 3. During lifetime antipsychotics were used by 98% of cases, benzodiazepines by 72% and antidepressants by 
42% and at the time of the study by 85%, 38% and 22% respectively. The lifetime and current use and doses of specific 
medication agents are presented in Supplementary Table 1. 
 3.3 The association between lifetime and current benzodiazepine and antidepressant medications and global cognition 
Lifetime cumulative DDD years of benzodiazepines or antidepressants, current DDD ratios and use of benzodiazepines 
or antidepressants at the time of the study were not significantly associated with global cognition (Table 4). In the post-
hoc analyses illustrated in Figure 1, those with high or medium lifetime DDD years of benzodiazepines had poorer global 
cognition than those with low lifetime DDD years. However, both low and high lifetime antidepressant doses were 
associated with better global cognitive performance than medium doses. 
 
3.4 The association between lifetime and current antipsychotic medication and global cognition 
Being without antipsychotic medication (range 0.9-20.3 years, mean 8.7 years) before the cognitive examination (n=9) 
was associated with better global cognitive performance (p=0.012), also when adjusted for gender and age of illness onset 
(p=0.006) or several other covariates, including illness severity measures (Table 5). Having long antipsychotic-free 
periods during treatment, excluding the time of cognitive examination (n=20), was not associated with global cognition 
(Table 5).  A higher proportion of time with antipsychotic use during the illness course, a higher proportion of time on 
antipsychotic polypharmacy, a higher current DDD ratio of antipsychotic medication and higher current antipsychotic 
polypharmacy had significant unadjusted associations with poorer global cognition, but not when adjusted (Table 5). 
Higher lifetime antipsychotic DDD years were significantly associated with poorer global cognition (p<0.001), when 
adjusted for gender, age of illness onset (p=0.018) and several other covariates (Table 5). The lifetime antipsychotic 
exposure of those who did not use antipsychotics at the cognitive examination was lower than in the rest of the sample 
(median 0.3 vs. 14.2 DDD years respectively). In the post hoc analyses, high and medium lifetime DDD years of 
antipsychotics were associated with poorer global cognition than low lifetime doses (Figure 1). 
 
4. Discussion 
 
4.1 Main results 
Lifetime and current doses of benzodiazepine and antidepressant medications were not significantly associated with 
global cognition. Not using antipsychotic medication for a relatively long time before the cognitive examination was 
associated with better global cognitive performance. However, antipsychotic-free periods of at least one year earlier 
during treatment were not associated with cognition. Other lifetime trends of antipsychotic use, current antipsychotic dose 
or polypharmacy were not significantly associated with cognition in adjusted models. 
 
4.2 Comparison with previous studies 
Benzodiazepines have been associated with cognitive impairment, both after acute administration [49] and in the long-
term treatment in a diagnostically heterogeneous sample [26]. Even with some degree of cognitive recovery, found also in 
schizophrenia after tapering or withdrawal of long-term benzodiazepine treatment [27, 28], the impairments persist [50]. 
Despite a paucity of studies conducted in schizophrenia and differences in exposure (use of benzodiazepines vs. 
cumulative dose, withdrawal vs. continued use) and setting (heterogeneous clinical vs. naturalistic sample), our results do 
not support the earlier findings of the association between use of benzodiazepines and poorer cognition.  
The short-term cognitive effects of antidepressants have been positive but clinically negligible [31, 32]. Not finding an 
association between cross-sectional or longitudinal, several years of antidepressant exposure and cognition is in line with 
the previous research.  
Our findings could indicate that benzodiazepines and antidepressants do not have strong cognitive effects in 
schizophrenia, but other explanations are also possible. In the subsample of 43 benzodiazepine and 25 antidepressant 
users, the lifetime exposure was relatively small (0.25 DDDs of benzodiazepines and 0.19 DDDs of antidepressants per 
year during the whole illness duration), which may remain under a threshold that could cause permanent, non-reversible 
cognitive effects. Additionally, most persons in our sample had used several medications and antipsychotics more than 
other medications, making it difficult to separate the effects of benzodiazepines and antidepressants.  
Antipsychotics have minimal cognitive effects in schizophrenia during the first years of treatment [7]. Antipsychotic 
polypharmacy has been connected with both negative [19] and neutral cognitive effects [51], but not with higher mortality 
than antipsychotic monotherapy [52]. A number of studies have documented associations between high-dose, long-term 
antipsychotic exposure and changes in the brain volume [53, 54, 55], functioning [56] and cognition [57, 16]. The 
association between higher lifetime antipsychotic DDD years and poorer cognition was not a novel finding, as we 
reported it in our prior study using chlorpromazine equivalent dose-years [17]. The method of measuring drug exposure 
did not significantly influence the main results, even though discrepancy has been found between chlorpromazine and 
DDD-equivalence estimations [58].  
The finding indicating that being without antipsychotics for a relatively long time before the cognitive examination is 
associated with better cognitive functioning, but antipsychotic-free periods at any other time during the treatment were 
not, can be seen to further support the view that antipsychotics do influence cognitive functioning in schizophrenia, but 
their cognitive effects may not be irreversible. 
Earlier studies have also identified a subpopulation of persons with schizophrenia who manage for many years with a 
lower dose or without antipsychotic medication and have markers of less severe illness [59] or better functional outcome 
[60]. In the NFBC 1966 being antipsychotic-free [61], having low cumulative lifetime antipsychotic dose or no drug-free 
periods of at least a month have also been associated with better functioning in midlife schizophrenia [37]. It is also likely 
that the persons in the current study (n=9), who managed for a long time (some for several years) without antipsychotics 
belong to this subgroup with a less severe illness course, perhaps a lower relapse risk and better preserved cognitive 
functioning. Also their lifetime exposure to antipsychotics was significantly lower than the exposure of the rest of the 
sample. Thus the finding of lower lifetime dose and better cognition may be related to a group of persons who do not use 
antipsychotics at the time of cognitive examination. 
Most patients with schizophrenia have a significantly higher relapse risk without antipsychotic medication [2, 62] and 
recurrent or persistent psychosis has been posited to be detrimental to cognition [63]. Treatment algorithms recommend 
maintenance antipsychotic treatment especially with multiple psychotic episodes, but also give room to controlled dose 
tapering and discontinuation strategies [2]. 
 
4.3 Theoretical discussion 
The cognitive effects of pharmacological agents rise from their potential to disrupt neurotransmission in areas of the 
brain responsible for cognitive functioning [49]. The cholinergic system projecting to the cortex and hippocampus is 
involved with memory, perception and attention. Anticholinergic qualities of medications, including many antipsychotic 
and antidepressant agents, impair cognitive functions and alterations in cholinergic function may mediate even longer-
term adverse cognitive effects [64]. The short-term and long-term negative cognitive effects of benzodiazepines may 
relate to the potentiation of y-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the brain [65]. The 
properties of antipsychotics, especially D2 antagonism with high-potency or high-occupancy binding due to high-dose 
exposure and glutaminergic inhibition by 5-TH-2A antagonism have been hypothesised to worsen the mesocortical 
hypodopaminergic state behind negative and cognitive symptoms in schizophrenia [66, 67, 68]. 
Antidepressants have been theorised to improve cognition via enhanced serotonergic, adrenergic and dopaminergic 
transmission, based on the mechanisms of specific agents, and less expected benefits with agents of higher anticholinergic 
activity, such as tricyclic antidepressants, but no relevant improvement has been observed adjunctive to antipsychotic 
treatment [31]. In the long-term use of benzodiazepines the development of tolerance to sedative effects [69] could 
possibly reduce the cognitive effects. 
 
4.5 Strengths and limitations 
The strength of this study is the naturalistic, non-selected sample with wide-ranging, reliable, prospective information 
based on interviews, medical records and linkage to register data. The longitudinal data on lifetime exposure to and timing 
of use of psychiatric medications are unique. Utilising DDD equivalents available for all medications instead of 
chlorpromazine equivalents has the benefit that they are more frequently updated and based on wider usage data [58]. 
Selection bias in this epidemiologically sound sample is minimised in comparison with selected, clinical populations and 
the results may be more generalisable to real-world schizophrenia. The attrition bias was also analysed thoroughly and it 
is unlikely that it would affect the results [16]. 
A limitation is the comparatively small sample size, especially in the subgroups of benzodiazepine and antidepressant 
users, which limits the power to detect the effects of medication and rule out type II error. Because of multiple medication 
variables analysed, the likelihood that some of the significant results may be chance findings can increase. Adherence 
could also reduce the reliability of the medication data. Access to medical records and not only registers on prescriptions 
or purchases has enabled taking known antipsychotic-free periods and measures of adherence into account resulting in 
considerably reliable cumulative antipsychotic variables accepted before in several peer-reviewed publications [16, 17, 
37, 55]. It would be relevant to analyse the cognitive effects of individual medications, instead of groups with 
heterogeneous mechanisms of action, and other psychiatric medications, such as mood stabilisers, but the sample size and 
use of many different medications by the same person during their lifetime did not allow for more detailed analyses. Two 
persons had used up to 14 different antipsychotic agents during their lives [16]. Also global cognitive performance may 
have been too insensitive to detect the effects of medications. 
Naturalistic studies are limited in showing causality, yet they may be optimal and the only realistic option to study 
long-term exposure to medications [33]. Longitudinal assessment of global cognition and symptoms, of which we do not 
have available data, could have enabled a more refined analysis of cognitive trajectories related to the illness process and 
other factors such as treatment. However, owing to our extensive database, we were able to control for a variety of most 
potential confounders associated with illness duration and both longitudinal and current severity at the time of the study 
and significantly reduce the risk of residual confounding. In this sample, transversal measurements reflect also 
longitudinal course: key areas of cognition [70] and antipsychotic medication [37] were quite stable in midlife. It is still 
possible that higher antipsychotic doses are given to those with a more severe or earlier onset illness and mark this more 
unfavourable illness course rather than cause poorer cognition. Similarly, managing without antipsychotics for many years 
may be a marker of a milder illness, which is also associated with preserved cognition. The possibility that long-term 
high-dose antipsychotic treatment could worsen cognitive deficits related to schizophrenia, supported by cumulating 
findings, should also be taken seriously. 
Interpretation of the findings of this study concerning the safety of long-term benzodiazepine and antidepressant use 
that was very low in our sample or risks and benefits of antipsychotic discontinuation should be cautious. Further study in 
larger populations of the long-term exposure to and optimal treatment strategies of psychiatric medications in 
schizophrenia is needed for clinical implications as well as identifying markers of a subpopulation that may manage with 
smaller doses or even without antipsychotic medication. 
  
4.6 Conclusions 
Polypharmacy continues to be a common practice in the treatment of schizophrenia and regular critical evaluation of 
medication is required to reduce it. To our knowledge, this is the first report on the association between lifetime 
cumulative benzodiazepine and antidepressant exposures and cognition in midlife schizophrenia. Based on these 
naturalistic data, low exposure to adjunctive benzodiazepine and antidepressant medications does not seem to greatly 
affect cognition nor explain the cognitive effects of antipsychotic medication in schizophrenia. 
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Figure titles  
 
Figure 1. Global cognition in low-, medium- and high-dose groups of lifetime cumulative DDD years of antipsychotics, 
benzodiazepines and antidepressants  
 
 
 
Figure 1 legend: The means and 95% confidence intervals of the cognitive composite score plotted in groups of 
cumulative DDD years of antipsychotics, benzodiazepines and antidepressants divided based on tertiles to high-, medium- 
and low-doses. Interpretation: Unadjusted, higher cumulative antipsychotic and benzodiazepine exposure was linearly 
associated with poorer cognition, but both low and high cumulative antidepressant doses were associated with better 
cognition than medium doses. 
 
 
 
 
 
 
 
 
 Table 1. Descriptions of the psychiatric medication variables 
Name of the variable Description of the variable 
Lifetime cumulative dose 
Lifetime DDD years of benzodiazepines A sum of DDDs of benzodiazepine medications the person had used, divided 
by 365.25 days, i.e. exposure to medication that corresponds using one 
defined daily dose per day for a year. 
Lifetime DDD years of antidepressants A sum of DDDs of antidepressant medications the person had used, divided 
by 365.25 days. 
Lifetime DDD years of antipsychotics A sum of DDDs of antipsychotic medications the person had used, divided by 
365.25 days. 
Current psychiatric medication 
Current DDD ratio of benzodiazepines The daily dose of benzodiazepines the person used at the time of the study 
divided by their DDD.  
Current DDD ratio of antidepressants The daily dose of antidepressants the person used at the time of the study 
divided by their DDD. 
Current DDD ratio of antipsychotics The daily dose of antipsychotics the person used at the time of the study 
divided by their DDD. 
Current use of benzodiazepines Use of benzodiazepines at the time of the study (yes/no). 
Current use of antidepressants Use of antidepressants at the time of the study (yes/no). 
Current antipsychotic polypharmacy Concomitant use of two or more antipsychotic medications at the time of the 
study (yes/no). 
Trends of lifetime use of antipsychotic medication 
Proportion of time with antipsychotic use Proportion of time during which antipsychotic medication was used of the 
whole duration of illness1 classified into three categories2: 1) < 50 %, 2) 50 – 
95 %, 3) > 95 % of time. 
Long antipsychotic-free periods during treatment Having one or more periods of at least one year without antipsychotic 
medication since the start of antipsychotic treatment (yes/no), but use of 
antipsychotics during the cognitive examination. 
Being without antipsychotic medication before the 
cognitive examination 
Having a break in antipsychotic medication at least 3 months before and 
during the cognitive examination (yes/no). 
Proportion of time on antipsychotic polypharmacy Proportion of time with concomitant use of two or more antipsychotic 
medications of the entire time during which antipsychotic medication was 
used classified into three classes2: 1) <5 %, 2) 5-40 %, 3) >40 % of time. 
DDD= defined daily dose, the average maintenance dose based on global health statistic evaluated by WHO [40], DDD ratio= used 
daily dose divided by defined daily dose; DDD year= exposure to medication that corresponds using one defined daily dose per day 
for a year. 1Duration of illness=time since the onset of illness or first psychiatric medication. 2The classes were chosen based on 
distribution of the data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2. Characteristics of the sample 
 Schizophrenia 
Sociodemographic factors  
Sex, n (%)  
Males 33 (55%) 
Education, n (%)1  
Low 33 (56%) 
Middle 15 (25%) 
High 11 (19%) 
Occupational status, n (%)  
working  18 (30%) 
on disability pension 35 (58%) 
Marital status, n (%)  
married/cohabiting 18 (30%) 
  
Clinical factors  
Current use of alcohol (g/day), median (IQR)1 1.2 (0-14.0) 
Alcohol abuse dg, n (%)1  
Yes 6 (10%) 
SOFAS, mean (SD) 50.7 (16.8) 
Onset age (years), mean (SD) 26.6 (6.3) 
Number of hospital treatment days, median (IQR) 210 (84-687) 
Psychiatric treatment status, n (%)  
no treatment contact 26 (43%) 
non-regular outpatient treatment 7 (12%) 
regular outpatient treatment 22 (37%) 
inpatient/institution 5 (8%) 
Diagnosis, n (%)  
schizophrenia 50 (83%) 
schizophreniform disorder 2 (3%) 
schizoaffective disorder 6 (10%) 
delusional disorder 2 (3%) 
  
Symptom severity  
CGI, mean (SD) 4.5 (1.4) 
PANSS, mean (SD)1 66.6 (23.5) 
Remission, n (%)1  
yes  16 (28%) 
SOFAS = Social and Occupational Functioning Assessment Scale, CGI = Clinical Global Impression, PANSS = Positive and  
Negative Syndrome Scale, IQR = interquartile range. Psychiatric treatment status: non-regular outpatient treatment =  
contact less than once per month or of unknown frequency, regular outpatient treatment = 1-4 times per month and  
inpatient/institution = being in psychiatric hospital treatment or sheltered home. 1There were missing data for 1 case  
in education, 1 case in current use of alcohol, 2 cases in PANSS, 2 cases in remission.  
 
 
 
 
 
 
 
 
 
 
 
  
Table 3. Lifetime use and current use of psychiatric medications at 43 years of age in schizophrenia (n=60). 
Medication groups Lifetime use Current use 
n (%) DDD years,  
Md (IQR)1 
n (%) DDD ratio,  
Md (IQR)1 
Any antipsychotic medication 59 (98%) 10.4 (5.0-29.7) 51 (85%) 1.2 (0.7-2.5) 
Benzodiazepines 43 (72%) 4.6 (1.2-16.1) 23 (38%) 1.0 (0.4-1.5) 
Antidepressants 25 (42%) 3.4 (0.8-12.9) 13 (22%) 1.3 (1.0-1.8) 
1Md=median and IQR=interquartile range were calculated for those with lifetime or current use of the specific medication, not for  
all cases. 
 
 
Table 4. The association between lifetime and current benzodiazepine and antidepressant medications and the cognitive 
composite score in schizophrenia at 43 years of age in linear regression analyses. 
 Model1 Model2 
 B (SE)1 Beta1 Sig1 B (SE)2 Beta2 Sig2 
Lifetime DDD years of benzodiazepines3 -0.16 (0.14) -0.18 0.278 -0.05 (0.15) -0.05 0.754 
Lifetime DDD years of antidepressants3 0.08 (0.21) 0.09 0.689 0.06 (0.20) 0.06 0.772 
Current DDD ratio of benzodiazepines3 -0.37 (0.24) -0.41 0.115 -0.25 (0.21) -0.27 0.238 
Current DDD ratio of antidepressants3 -0.60 (0.42) -0.32 0.148 -0.78 (0.45) -0.42 0.081 
Current use of benzodiazepines -0.15 (0.27) -0.07 0.571 0.08 (0.26) 0.04 0.761 
Current use of antidepressants 0.48 (0.31) 0.20 0.127 0.19 (0.33) 0.08 0.561 
B=unstandardised regression coefficient, SE=standard error, Beta=standardised regression coefficient, Sig=statistical significance.  
1Unadjusted model. 2Adjusted for gender and onset age. 3The analyses were completed in a group of those cases that had used the 
medication and those with no use were excluded. 
 
28 
 
Table 5. The association between lifetime and current antipsychotic medication variables and cognitive composite score in schizophrenia at 43 years of age in linear 
regression analyses. 
 Model1 Model2 Model3 Model4 
 B (SE)1 Beta1 Sig1 B (SE)2 Beta2 Sig2 B (SE)3 Beta3 Sig3 B (SE)4 Beta4 Sig4 
Lifetime DDD years of antipsychotics -0.37 (0.11) -0.42 <0.001 -0.28 (0.12) -0.32 0.018 -0.34 (0.15) -0.39 0.020 -0.24 (0.13) -0.28 0.066 
Proportion of time with antipsychotic use -0.34 (0.17) -0.25 0.046 -0.32 (0.16) -0.23 0.051 -0.31 (0.17) -0.23 0.066 -0.28 (0.17) -0.20 0.107 
Long antipsychotic-free periods during 
treatment 
-0.07 (0.28) -0.03 0.809 0.10 (0.27) 0.05 0.722 0.12 (0.27) 0.06 0.653 0.11 (0.28) 0.05 0.689 
Being without antipsychotic medication 
before the cognitive examination 
0.89 (0.35) 0.32 0.012 0.90 (0.33) 0.32 0.006 0.98 (0.36) 0.35 0.007 0.81 (0.35) 0.29 0.021 
Proportion of time on antipsychotic 
polypharmacy 
-0.35 (0.16) -0.28 0.029 -0.24 (0.16) -0.19 0.121 -0.24 (0.18) -0.19 0.173 -0.20 (0.17) -0.16 0.235 
Current DDD ratio of antipsychotics -0.23 (0.10) -0.30 0.017 -0.14 (0.10) -0.18 0.181 -0.13 (0.11) -0.17 0.258 -0.12 (0.10) -0.15 0.251 
Current antipsychotic polypharmacy -0.74 (0.30) -0.31 0.012 -0.49 (0.31) -0.21 0.110 -0.47 (0.33) -0.20 0.152 -0.42 (0.33) -0.18 0.202 
B=unstandardised regression coefficient, SE=standard error, Beta=standardised regression coefficient, Sig=statistical significance. Statistically significant results in bold. 1Unadjusted model. 
2Adjusted for gender and onset age. 3Adjusted for gender, onset age and logarithmic transformation of cumulative lifetime hospital treatment days. 4Adjusted for gender, onset age and PANSS 
positive symptoms. 
 
When adjusted, in addition to gender and onset age, for other covariates (one per model) in separate models: 
Being without antipsychotic medication before the cognitive examination was significantly associated with cognition additionally when adjusted with remission (B=0.82, SE=0.36, Beta=0.29, 
Sig=0.025), educational level (B=0.92, SE=0.33, Beta=0.33, Sig=0.005), current benzodiazepine use (B=0.91, SE=0.33, Beta=0.32, Sig=0.006), current antidepressant use (B=0.90, SE=0.33, 
Beta=0.32, Sig=0.006) and PANSS negative symptoms (B=0.67, SE=0.34, Beta=0.24, Sig=0.046).  
 
The association between being without antipsychotic medication before the cognitive examination and cognition was not significant only, when adjusted in addition to gender and onset age for 
PANSS disorganisation symptoms (B=0.39, SE=0.31, Beta=0.14, Sig=0.215).  
 
Lifetime DDD years of any antipsychotics was significantly associated with cognition also when adjusted for educational level (B=-0.29, SE=0.12, Beta=-0.33, Sig=0.017), current 
benzodiazepine use (B=-0.29, SE=0.12, Beta=-0.33, Sig=0.016) or current antidepressant use (B=-0.29, SE=0.12, Beta=-0.33, Sig=0.015).  
 
There were no other significant associations between the other antipsychotic medication variables and cognition in the models described before.  
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Supplementary material, Methods 
 
Background variables and covariates 
Age of illness onset, defined as the age when the first evident psychotic symptoms emerged, was ascertained from 
medical records. 
Level of education was based on questionnaire information gained in the 43-year study on the level of basic 
education (O level, 9 years or A level, 12 years) and vocational education (none, course or school, currently studying, 
college, polytechnic or university) which were combined and classified into three categories: low = O level with low 
vocational education (none, course or school or currently studying), middle = O level with high vocational education 
(college, polytechnic or university) or A level with low vocational education and high = A level with high vocational 
education. 
Occupational status at the time of the 43-year study was classified into three categories: 1) working, if the subjects 
were studying, on maternity leave or in full-time or part-time work, 2) on disability pension, if they were retired 
because of psychiatric or other illness or 3) not working, if they were unemployed, or outside of working life for other 
reasons. Information was ascertained in an interview in the 43-years study and missing information was completed 
with Finnish Centre for Pension registers data. 
Alcohol abuse diagnosis included subjects with an earlier or current diagnosis of either alcohol abuse or 
dependency evaluated in the SCID I interview at the 43-year study. 
PANSS (Positive and Negative Syndrome Scale) [1] scores were evaluated in a PANSS specific interview at the 
43-years study. PANSS total symptoms were measured from one week before the interview and divided into positive, 
negative and disorganisation symptoms based on the model described by van der Gaag et al. [2]. PANSS was also 
utilised in determining remission status (more below).  
The Severity of Illness subscale of the CGI (Clinical Global Impression) [3], ranging from 1 (not ill at all) to 7 
(among the most extremely ill), was ascertained in the interview at the 43-year study. 
Cumulative number of hospital treatment days was obtained from the Care Register for Health Care (formerly 
Finnish Hospital Discharge Register). 
Psychiatric treatment status was ascertained in the interview at the 43-year study by asking about previous and 
current psychiatric treatment contacts (place and time of starting the contact, frequency of visits) and grouped to four 
categories: no treatment contact, non-regular outpatient treatment (less frequent than once per month or of unknown 
frequency), regular outpatient treatment (visits in the psychiatric services or outpatient rehabilitation group at least 
once and mostly 1-4 times per month), and inpatient/institution (psychiatric hospital treatment or living in a sheltered 
home). 
Remission, according to the Andreasen symptomatic criteria [4], was defined as having no symptoms (PANSS) at 
the time of the 43-year study and no psychiatric hospital treatments in 6 months before the study. 
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Supplementary Table 1. Lifetime use and current use of psychiatric medications at 43 years of age in  
schizophrenia (n=60). 
ATC code Generic name Lifetime use Current use 
n (%) DDD years,  
mean (Sd) 
n (%) DDD,  
mean (Sd) 
Antipsychotic medication 59 (98%) 18.2 (20.2) 51 (85%) 1.6 (1.3) 
 
Typical antipsychotics 
 
54 (90%) 
 
9.9 (14.0) 
 
19 (32%) 
 
0.7 (0.8) 
N05AA01 Chlorpromazine 22 (37%) 2.4 (5.8) - - 
N05AA02 Levomepromazine 26 (43%) 0.9 (2.1) 4 (7%) 0.4 (0.3) 
N05AA03 Promazine 20 (33%) 0.5 (0.9) 1 (2%) 0.7 
N05AB01 Dixyrazine 1 (2%) 0.01 - - 
N05AB02 Fluphenazine 2 (3%) 20.1 (28.5) - - 
N05AB03 Perphenazine 36 (60%) 1.4 (2.1) 6 (10%) 0.6 (0.4) 
N05AB08 Thioproperazine 1 (2%) 4.3 - - 
N05AC01 Periciazine 1 (2%) 0.04 - - 
N05AC02 Thioridazine 38 (63%) 4.2 (6.3) 1 (2%) 0.7 
N05AC04 Pipotiazine 3 (5%) 2.6 (3.8) - - 
N05AD01 Haloperidol 40 (67%) 2.4 (3.9) 2 (3%) 0.5 (0.07) 
N05AD03 Melperone 3 (5%) 0.03 (0.04) - - 
N05AF01 Flupentixol 4 (7%) 0.4 (0.4) - - 
N05AF03 Chlorprothixene 15 (25%) 1.1 (1.7) 4 (7%) 0.5 (0.2) 
N05AF05 Zuclopenthixol 21 (35%) 3.2 (5.6) 3 (5%) 1.5 (0.9) 
N05AG02 Pimozide 1 (2%) 0.4 - - 
N05AL01 Sulpiride 7 (12%) 0.1 (0.1) - - 
N05AL04 Remoxipride 2 (3%) 0.1 (0.006) - - 
 
Atypical antipsychotics 
 
49 (82%) 
 
11.0 (9.9) 
 
43 (72%) 
 
1.6 (0.9) 
N05AE03 Sertindole 3 (5%) 0.4 (0.4) - - 
N05AE04 Ziprasidone 1 (2%) 0.06 - - 
N05AH02 Clozapine 16 (27%) 12.1 (13.3) 11 (18%) 1.4 (0.4) 
N05AH03 Olanzapine 31 (52%) 6.7 (7.6) 20 (33%) 1.7 (0.9) 
N05AH04 Quetiapine 19 (32%) 2.3 (3.9) 7 (12%) 1.1 (0.9) 
N05AH05 Asenapine 1 (2%) 0.03 - - 
N05AX08 Risperidone 36 (60%) 2.2 (3.7) 4 (7%) 0.9 (0.5) 
N05AX12 Aripiprazole 11 (18%) 1.1 (1.2) 7 (12%) 0.9 (0.8) 
 
Benzodiazepines 
 
43 (72%) 
 
8.9 (10.2) 
 
23 (38%) 
 
1.2 (1.1) 
N03AE01 Clonazepam 9 (15%) 2.3 (3.2) 3 (5%) 0.6 (0.8) 
N05BA01   Diazepam  37 (62%) 3.7 (5.2) 8 (13%) 0.9 (0.9) 
N05BA02   Chlordiazepoxide  9 (15%) 2.2 (5.2) 1 (2%) 0.8 
N05BA04   Oxazepam  27 (45%) 1.7 (3.4) 5 (8%) 0.4 (0.3) 
N05BA05   Potassium clorazepate  9 (15%) 1.1 (1.6) - - 
N05BA06   Lorazepam  13 (22%) 0.8 (0.6) 4 (7%) 1.3 (0.8) 
N05BA12   Alprazolam  4 (7%) 0.3 (0.2) - - 
N05CD02   Nitrazepam  7 (12%) 0.6 (0.9) - - 
N05CD05   Triazolam  3 (5%) 0.6 (0.7) - - 
N05CD07   Temazepam  34 (57%) 2.4 (3.6) 7 (12%) 0.9 (0.5) 
N05CD08   Midazolam  4 (7%) 0.009 (0.009) - - 
N05CF01   Zopiclone  25 (42%) 1.8 (3.2) 5 (8%) 0.7 (0.3) 
N05CF02   Zolpidem  5 (8%) 1.0 (0.9) - - 
 
 
Antidepressants 
 
 
25 (42%) 
 
 
6.9 (6.7) 
 
 
13 (22%) 
 
 
1.3 (0.5) 
N06AA04 Clomipramine  1 (2%) 0.008 - - 
N06AA09 Amitriptyline  10 (17%) 2.2 (3.1) 3 (5%) 0.9 (0.7) 
N06AA10 Nortriptyline  1 (2%) 0.007 1 (2%) 0.07 
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N06AA12 Doxepin  3 (5%) 0.1 (0.2) 1 (2%) 0.06 
N06AA21 Maprotiline  1 (2%) 0.6 - - 
N06AB03 Fluoxetine  9 (15%) 3.5 (4.7) 3 (5%) 1.3 (0.6) 
N06AB04 Citalopram  13 (22%) 4.1 (5.8) 2 (3%) 1.1 (0.2) 
N06AB05 Paroxetine  4 (7%) 7.0 (4.6) 1 (2%) 2.0 
N06AB06 Sertraline  5 (8%) 3.4 (3.2) 1 (2%) 2.0 
N06AB08 Fluvoxamine  1 (2%) 0.5 - - 
N06AB10 Escitalopram  1 (2%) 1.0 1 (2%) 1.0 
N06AG02 Moclobemide  1 (2%) 0.004 - - 
N06AX03 Mianserin  2 (3%) 1.4 (1.9) - - 
N06AX11 Mirtazapine  4 (7%) 3.2 (3.9) 2 (3%) 1.0 (0.7) 
N06AX16 Venlafaxine  1 (2%) 2.0 1 (2%) 0.8 
N06AX17 Milnacipran  1 (2%) 0.09 - - 
 
Anticholinergic agents 
    
N04AA02   Biperiden 26 (43%) 1.4 (2.7) - - 
 
Other medications 
    
G02CB01 Bromocriptine 1 (2%) 0.01 - - 
N03AB02   Phenytoin  2 (3%) 6.9 (8.5) - - 
N03AF01   Carbamazepine  5 (8%) 2.9 (4.3) 1 (2%) 0.07 
N03AF02   Oxcarbazepine  1 (2%) 0.06 - - 
N03AG01   Valproic acid  10 (17%) 6.3 (5.8) 10 (17%) 0.8 (0.4) 
N03AX09   Lamotrigine  3 (5%) 0.5 (0.9) 1 (2%) 0.7 
N03AX11   Topiramate  1 (2%) 1.4 - - 
N03AX14   Levetiracetam  1 (2%) 0.01 - - 
N03AX16   Pregabalin  1 (2%) 0.03 - - 
N04BC05 Pramipexole 1 (2%) 0.02 - - 
N05BB01   Hydroxyzine  8 (13%) 0.3 (0.4) 1 (2%) 1.3 
N05CC01 Chloral hydrate 1 (2%) 0.002 - - 
N05CH01 Melatonin  2 (3%) 0.9 (1.2) 2 (3%) 1.5 (0.7) 
R06AD02 Promethazine 1 (2%) 0.003 - - 
Means and standard deviations (Sd) are calculated for those who have used the specific medication. 
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